Canopy Immuno-Therapeutics
June 22, 2026
Theater 3
Type: Company Presentation
Focus Area:
Immunology
Canopy is developing first-in-class Antigen-Drug Conjugates (AgDCs) for antibody-mediated autoimmunity. Using disease-defining autoantigens, AgDCs combine both the highly selective clearance of pathogenic autoantibodies and the elimination of the entire lineage of autoreactive B-cell clones, while preserving >99% of protective immunity, aiming for years-long, disease-modifying activity.
Built of 3 functional domains (Autoantigen, Inhibitory Fc, Linker-payload), AgDCs deliver dual, independent MOAs: Ultra-rapid and highly-specific autoantibody clearance, combined with targeted killing of autoreactive B cells. AgDCs exceed the safety and efficacy of FcRni and anti-B-cell agents combined, offering a non-immunosuppressive, potentially curative immune-editing.
FIH Phase 1 in MG is planned for Q4/26.
The company is led by Founder/CEO Dr. Kfir Oved, Chairman Dr. Cedric Francois (APLS), and board member John Cox (DYN), and supported by world-class investors and advisory.
Company HQ City:
Megadim
Company HQ State:
Israel
Company HQ Country:
Israel
Year Founded:
2020
Lead Product in Development:
MGAC-007
CEO
Dr. Kfir Oved
Development Phase of Lead Product
Phase I
Number of Unlicensed Products Looking for Licensing
5
When you expect your next catalyst update?
Q1/2027
What is your next catalyst (value inflection) update?
Clinical readout - Phase 1
Primary Speaker
)
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}